In­smed’s PhII smokes and sput­ters, but re­searchers her­ald enough sur­pris­ing­ly pos­i­tive da­ta to roar on Wall Street

There was plen­ty not to like in In­smed’s Phase II read­out of an an­ti-in­flam­ma­to­ry drug dubbed INS1007.

The dose re­sponse didn’t pan out and in fact, the high dose missed on a key end­point that could be the piv­otal goal need­ed for an ap­proval. But with sev­er­al an­a­lysts ex­pect­ing the whole thing to be a bust, in­vestors cheered on ev­i­dence of pos­i­tive ef­fi­ca­cy in treat­ing non-cys­tic fi­bro­sis bronchiec­ta­sis and ran up the stock price $IN­SM by 40%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.